Jack Allen
Stock Analyst at Baird
(4.14)
# 518
Out of 4,611 analysts
37
Total ratings
38.71%
Success rate
25.89%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Jack Allen
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TIL Instil Bio | Reiterates: Outperform | $180 | $48.48 | +271.29% | 9 | Sep 16, 2024 | |
| BLUE bluebird bio | Maintains: Outperform | $7 → $6 | $0.57 | +952.63% | 3 | Aug 15, 2024 | |
| MREO Mereo BioPharma Group | Initiates: Outperform | $8 | $4.40 | +81.82% | 1 | Jun 13, 2024 | |
| CRSP CRISPR Therapeutics AG | Maintains: Neutral | $46 → $52 | $45.37 | +14.61% | 2 | May 9, 2024 | |
| ACLX Arcellx | Maintains: Outperform | $63 → $77 | $78.23 | -1.57% | 4 | Feb 29, 2024 | |
| IMCR Immunocore Holdings | Initiates: Outperform | $84 | $31.11 | +170.01% | 1 | Oct 31, 2023 | |
| TSHA Taysha Gene Therapies | Maintains: Outperform | $6 → $8 | $2.01 | +298.01% | 4 | Aug 15, 2023 | |
| CARM Carisma Therapeutics | Reiterates: Outperform | $10 | $0.95 | +958.20% | 2 | Jun 28, 2023 | |
| VOR Vor Biopharma | Maintains: Outperform | $38 → $22 | $0.67 | +3,177.22% | 2 | Mar 24, 2023 | |
| NTLA Intellia Therapeutics | Maintains: Neutral | $58 → $42 | $17.99 | +133.46% | 1 | Feb 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $12 | $2.70 | +344.44% | 2 | Jan 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $5 | $0.91 | +449.45% | 1 | Nov 2, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $28 | $3.22 | +769.57% | 1 | Jun 3, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | n/a | $1.89 | - | 2 | May 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $26 | $0.72 | +3,525.71% | 1 | Nov 9, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $6 → $9 | $7.04 | +27.84% | 1 | Oct 7, 2021 |
Instil Bio
Sep 16, 2024
Reiterates: Outperform
Price Target: $180
Current: $48.48
Upside: +271.29%
bluebird bio
Aug 15, 2024
Maintains: Outperform
Price Target: $7 → $6
Current: $0.57
Upside: +952.63%
Mereo BioPharma Group
Jun 13, 2024
Initiates: Outperform
Price Target: $8
Current: $4.40
Upside: +81.82%
CRISPR Therapeutics AG
May 9, 2024
Maintains: Neutral
Price Target: $46 → $52
Current: $45.37
Upside: +14.61%
Arcellx
Feb 29, 2024
Maintains: Outperform
Price Target: $63 → $77
Current: $78.23
Upside: -1.57%
Immunocore Holdings
Oct 31, 2023
Initiates: Outperform
Price Target: $84
Current: $31.11
Upside: +170.01%
Taysha Gene Therapies
Aug 15, 2023
Maintains: Outperform
Price Target: $6 → $8
Current: $2.01
Upside: +298.01%
Carisma Therapeutics
Jun 28, 2023
Reiterates: Outperform
Price Target: $10
Current: $0.95
Upside: +958.20%
Vor Biopharma
Mar 24, 2023
Maintains: Outperform
Price Target: $38 → $22
Current: $0.67
Upside: +3,177.22%
Intellia Therapeutics
Feb 24, 2023
Maintains: Neutral
Price Target: $58 → $42
Current: $17.99
Upside: +133.46%
Jan 6, 2023
Upgrades: Outperform
Price Target: $12
Current: $2.70
Upside: +344.44%
Nov 2, 2022
Initiates: Outperform
Price Target: $5
Current: $0.91
Upside: +449.45%
Jun 3, 2022
Initiates: Neutral
Price Target: $28
Current: $3.22
Upside: +769.57%
May 18, 2022
Upgrades: Outperform
Price Target: n/a
Current: $1.89
Upside: -
Nov 9, 2021
Initiates: Outperform
Price Target: $26
Current: $0.72
Upside: +3,525.71%
Oct 7, 2021
Upgrades: Outperform
Price Target: $6 → $9
Current: $7.04
Upside: +27.84%